The MYC Inhibitor, OMO-103, Demonstrates Safety and Preliminary Activity

Skip Nav Destination

February 15, 2024

Major Finding: OMO-103 shows safety as well as preliminary signs of drug activity in advanced solid tumors.

Concept: Target engagement and soluble immune-related potential response and predictive markers were demonstrated.

Impact: This first-in-modality trial indicates that further investigation into specific indications for OMO-103 is needed.

DOI:https://doi.org/10.1158/2159-8290.CD-RW2024-025

Article Type: Research Watch

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.

The MYC Inhibitor, OMO-103, Demonstrates Safety and Preliminary Activity Available to Purchase